Is MannKind Back on Track?

Biotech MannKind (Nasdaq: MNKD  ) , which is developing the inhalable insulin product Afrezza, released its third-quarter earnings report after the market closed on Thursday. There were several key updates regarding the company's financial situation and cash burn.

In the following video, health-care analysts Max Macaluso and David Williamson discuss these results and a few issues investors need to watch.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

David Williamson owns shares of Pfizer. Max Macaluso, Ph.D., and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 05, 2012, at 12:20 PM, WCoastGuynCA wrote:

    Today Bank of America issued a "buy" rating on Mannkind with a $3.00 price target on the stock.

    It's my opinion that the share price will hit the $5.00 or higher when Afrezza is approved and could easily hit the $10.00 range if Mannkind partners with a major drug company to market Afrezza.

    Beyond that who knows how high the share price could go if Afrezza is a commercial success.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2094173, ~/Articles/ArticleHandler.aspx, 12/19/2014 3:56:47 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement